Highlights

  • Epiminder completed its A$125 million IPO in December 2025, supporting commercialisation plans through 2028.
  • The company reached 50 DETECT study enrolments ahead of guidance, with 20 leading US clinical sites actively participating.
  • US Medicare proposed a 2027 payment level of US$31,600 for the Minder procedure.
  • Approximately 200 next-generation Minder devices have been built and are undergoing testing.
  • Epiminder ended FY26 with cash of $75.8 million, with second-half cash outflow below previous guidance.

Epiminder Limited (ASX:EPI) released its FY26 and Q4 operational update, outlining progress across its DETECT reimbursement study, next-generation Minder® device development and commercialisation pathway for its epilepsy monitoring technology.

The company highlighted several operational milestones during FY26, including the successful completion of its A$125 million initial public offering (IPO), expansion of its US clinical site network and faster-than-expected patient enrolment progress in the DETECT study.

Epiminder shares traded at AUD 0.26, down 3.64% during the afternoon session on 30 July 2026. The stock remains down 79.77% over the past year, while investors continue monitoring the company’s progress toward reimbursement validation, product development milestones and planned commercialisation of the Minder System.

Epiminder Develops Continuous EEG Monitoring Technology for Epilepsy Care

Epiminder is a medical device and information solutions company focused on developing diagnostic and treatment tools for epilepsy and other seizure disorders where continuous monitoring is required.

The company’s flagship Minder® System is a minimally invasive implantable continuous EEG Monitoring (iCEM®) device designed to provide clinicians and patients with long-term information on brain electrical activity.

The device continuously records bilateral subscalp EEG data and transmits information through an external wearable and smartphone application to a secure cloud platform.

Unlike short-duration monitoring approaches, Minder is designed to enable monitoring over extended periods while patients continue normal daily activities.

The Minder System received FDA authorisation through the de novo pathway and is currently being used in the DETECT post-market study.

FY26 Marks Progress Toward Commercialisation Strategy

Epiminder described FY26 as a transformational year, supported by the completion of its IPO and continued advancement of its clinical and product development programs.

The A$125 million IPO completed in December 2025 strengthened the company’s balance sheet and provided funding support for the DETECT reimbursement study, development of the next-generation Minder System and planned commercialisation activities.

Following IPO costs and settlement of historical research and development tax claims totalling $15.8 million, Epiminder commenced 2026 with approximately $90 million in cash and no debt.

The company also stated that it hedged most of its US dollar expenditure for FY27 at a rate approximately 10% higher than planned, extending its available cash runway.

Epiminder expects its current funding position to support completion of key reimbursement and product development programs while preparing for broader commercial rollout.

DETECT Study Progresses Ahead of Previous Enrolment Guidance

A major operational milestone during FY26 was progress in the DETECT reimbursement study.

The company reached 50 patient enrolments on 16 July 2026, ahead of its previous guidance of mid-Q3 CY2026.

Epiminder remains focused on enrolling 210 patients by the end of FY27.

The DETECT study is designed to demonstrate whether continuous EEG monitoring using Minder can provide advantages over standard care in identifying clinically actionable events in patients with drug-resistant epilepsy.

The study includes up to 25 US clinical sites, with 20 leading medical institutions currently active in patient enrolment.

Participating institutions include the Mayo Clinic, Harvard, Stanford, Yale, Duke and the University of Pennsylvania.

The first US patient was implanted with Minder in January 2026 at the Perelman School of Medicine at the University of Pennsylvania.

Epiminder stated that growing participation from leading US medical institutions reflects continued interest in long-term continuous EEG monitoring and the potential applications of Minder for epilepsy patients.

Medicare Reimbursement Progress Supports Commercial Pathway

Epiminder also provided an update on the reimbursement environment for the Minder procedure.

US Medicare proposed a 2027 payment level of US$31,600 for the Minder procedure in July 2026.

The proposed payment compares with the CY2026 Medicare payment level of US$27,700, which represented a 23% increase from the initial proposed ruling of US$22,500.

The proposed 2027 payment level is expected to be finalised in November 2026.

Epiminder stated that these reimbursement levels support its anticipated average selling price of US$25,000 as the company works to establish a market for long-term EEG monitoring in the United States.

The Minder System also remains eligible for Transitional Pass-Through payment for outpatient procedures, with the company planning to apply for this additional payment when commercial launch timing is appropriate.

Next-Generation Minder Device Development Advances

Alongside clinical and reimbursement progress, Epiminder continued advancing development of its next-generation Minder device.

The company has built approximately 200 next-generation devices, which are currently undergoing detailed testing, including biocompatibility assessments.

Design completion remains targeted for the end of the first half of calendar year 2027.

The next-generation Minder development program represents one of the company’s key priorities for FY27.

Epiminder expects the program to support future commercialisation plans by providing the product foundation required for broader market adoption.

Financial Position Provides Support Through Commercialisation Phase

Epiminder reported cash and cash equivalents of $75.8 million as at 30 June 2026.

During the second half of FY26, net cash outflow was $13.9 million, below the company’s previous guidance of approximately $20 million.

Epiminder stated that the lower cash outflow primarily reflected working capital timing benefits, which are expected to reverse during FY27.

For FY26, operating activities resulted in net cash outflow of $43.3 million, including DETECT costs, next-generation Minder development expenses, staff costs and other corporate activities.

The company reported second-half DETECT costs of $2.0 million and research and development expenditure associated with the next-generation Minder system.

Epiminder also confirmed that it has sufficient cash resources to fund completion of the DETECT reimbursement program, next-generation Minder development and commercialisation activities into 2028.

FY27 Expected to Be a Key Development Period

Looking ahead, Epiminder identified two major priorities for FY27: completing enrolment of 210 patients in DETECT and completing the design program for the next-generation Minder device.

The company expects FY27 net cash outflow to be approximately $45 million to $48 million, reflecting peak activity across the reimbursement study and device development program.

Epiminder expects costs associated with these programs to reduce significantly in FY28.

The company is targeting the commencement of commercial sales from early 2028.

With the DETECT study progressing and product development advancing, Epiminder is focused on establishing the clinical, reimbursement and operational foundations required for commercial launch.

Minder System Designed to Transform Long-Term Epilepsy Monitoring

The Minder System is designed to provide continuous monitoring of brain electrical activity over extended periods.

The technology combines an implanted monitoring device with external wearable technology and cloud-based data analysis.

Epiminder believes long-term monitoring can provide clinicians with additional information to support epilepsy diagnosis, seizure classification and treatment decisions.

The company’s first-in-human UMPIRE multicentre trial, published in Epilepsia in 2025, demonstrated safety and high-quality signal acquisition over extended monitoring periods.

Through DETECT and future commercialisation activities, Epiminder continues working toward establishing broader adoption of continuous EEG monitoring.

What This Means for Investors?

Epiminder’s FY26 update highlighted progress across its key development priorities, including clinical enrolment, reimbursement preparation and next-generation product development.

The company reached 50 DETECT enrolments ahead of previous guidance, expanded participation across 20 leading US medical institutions and received a proposed increase in Medicare payment levels for the Minder procedure.

The company’s $75.8 million cash position provides funding support as it advances toward completion of the DETECT study and next-generation device development.

Investors are likely to continue monitoring DETECT enrolment progress, Medicare reimbursement developments and the company’s pathway toward commercial sales targeted for early 2028.

Answer: Minder is a minimally invasive implantable continuous EEG Monitoring device designed to provide long-term monitoring of brain electrical activity for epilepsy patients through implanted sensors, wearable technology and cloud-based data analysis.

Answer: Epiminder reached 50 patient enrolments in DETECT on 16 July 2026, ahead of previous guidance. The study has 20 active US clinical sites and the company remains focused on reaching 210 enrolments by the end of FY27.

Answer: US Medicare proposed a CY2027 payment level of US$31,600 for the Minder procedure, compared with the CY2026 payment level of US$27,700.

Answer: Epiminder reported cash and cash equivalents of $75.8 million as at 30 June 2026. The company stated that its funding position supports key programs through 2028.

Answer: Epiminder is currently targeting the commencement of commercial sales from early 2028, following completion of its reimbursement program and next-generation Minder development activities.